Literature DB >> 8537058

Mesalazine induced exacerbation of ulcerative colitis.

K C Kapur1, G T Williams, M C Allison.   

Abstract

5-Aminosalicylic acid (5-ASA) compounds occasionally exacerbate diarrhoea in patients with inflammatory bowel disease. This is thought to be due to a secretory mechanism in most cases. A patient with presumed intolerance to sulphasalazine and 5-ASA preparations who developed endoscopic and histological evidence of disease relapse after a rectal challenge with mesalazine is reported.

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 8537058      PMCID： PMC1382949          DOI： 10.1136/gut.37.6.838

Source DB:  PubMed          Journal:  Gut        ISSN： 0017-5749            Impact factor:   23.059


  13 in total

1.  Adverse effects with oral 5-aminosalicyclic acid.

Authors:  J M Fardy; D A Lloyd; R P Reynolds
Journal:  J Clin Gastroenterol       Date:  1988-12       Impact factor: 3.062

2.  Bloody diarrhea--a new complication of sulfasalazine.

Authors:  S L Werlin; R J Grand
Journal:  J Pediatr       Date:  1978-03       Impact factor: 4.406

3.  Acute ulcerative colitis--a rare complication of sulfasalazine therapy.

Authors:  H Ruppin; S Domschke
Journal:  Hepatogastroenterology       Date:  1984-08

4.  Exacerbation of diarrhoea and pain in patients treated with 5-aminosalicylic acid for ulcerative colitis.

Authors:  C A Austin; P A Cann; T H Jones; C D Holdsworth
Journal:  Lancet       Date:  1984-04-21       Impact factor: 79.321

5.  Sulfasalazine-induced exacerbation of ulcerative colitis.

Authors:  A G Schwartz; S R Targan; A Saxon; W M Weinstein
Journal:  N Engl J Med       Date:  1982-02-18       Impact factor: 91.245

6.  Azodisal sodium in the treatment of ulcerative colitis. A study of tolerance and relapse-prevention properties.

Authors:  H Sandberg-Gertzén; G Järnerot; W Kraaz
Journal:  Gastroenterology       Date:  1986-04       Impact factor: 22.682

7.  Relapse of ulcerative proctocolitis during treatment with non-steroidal anti-inflammatory drugs.

Authors:  D S Rampton; G E Sladen
Journal:  Postgrad Med J       Date:  1981-05       Impact factor: 2.401

8.  Effect of olsalazine and mesalazine on human ileal and colonic (Na+ + K+)-ATPase. A possible diarrhogenic factor?

Authors:  C Scheurlen; H Allgayer; W Kruis; E Erdmann; T Sauerbruch
Journal:  Clin Investig       Date:  1993-04

9.  Clinical tolerance to three 5-aminosalicylic acid releasing preparations in patients with inflammatory bowel disease intolerant or allergic to sulphasalazine.

Authors:  M H Giaffer; C J O'Brien; C D Holdsworth
Journal:  Aliment Pharmacol Ther       Date:  1992-02       Impact factor: 8.171

Review 10.  Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans.

Authors:  I Bjarnason; J Hayllar; A J MacPherson; A S Russell
Journal:  Gastroenterology       Date:  1993-06       Impact factor: 22.682
View more
  17 in total

1.  Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease.

Authors:  Sara Lewin; Fernando S Velayos
Journal:  Gastroenterol Hepatol (N Y)       Date:  2020-09

2.  Inflammatory Bowel Disease After Age 60.

Authors:  David A. Greenwald; Lawrence J. Brandt
Journal:  Curr Treat Options Gastroenterol       Date:  2003-06

Review 3.  Elderly patients and inflammatory bowel disease.

Authors:  Danielle Nimmons; Jimmy K Limdi
Journal:  World J Gastrointest Pharmacol Ther       Date:  2016-02-06

4.  Mesalamine induced symptom exacerbation of ulcerative colitis: Case report and brief discussion.

Authors:  Maneesh Kumar Gupta; Scott Pollack; John J Hutchings
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-12-06

Review 5.  Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

6.  Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.

Authors:  Ryan C Ungaro; Berkeley N Limketkai; Jean-Frederic Colombel; Tine Jess; Camilla Bjørn Jensen; Kristine Højgaard Allin; Manasi Agrawal; Thomas Ullman
Journal:  Gut       Date:  2018-11-12       Impact factor: 23.059

Review 7.  Strategies for the care of adults hospitalized for active ulcerative colitis.

Authors:  Suresh Pola; Derek Patel; Sonia Ramamoorthy; Elisabeth McLemore; Marianne Fahmy; Jesus Rivera-Nieves; John T Chang; Elisabeth Evans; Michael Docherty; Mark Talamini; William J Sandborn
Journal:  Clin Gastroenterol Hepatol       Date:  2012-07-24       Impact factor: 11.382

8.  Severe and Rapid Progression in Very Early-Onset Chronic Granulomatous Disease-Associated Colitis.

Authors:  Toshinao Kawai; Katsuhiro Arai; Shizuko Harayama; Yumiko Nakazawa; Fumihiro Goto; Takanobu Maekawa; Eiichiro Tamura; Toru Uchiyama; Masafumi Onodera
Journal:  J Clin Immunol       Date:  2015-08-02       Impact factor: 8.317

9.  Mesalamine treatment mimicking relapse in a child with ulcerative colitis.

Authors:  Iva Hojsak; Ana M Pavić; Sanja Kolaček
Journal:  World J Pediatr       Date:  2014-06-28       Impact factor: 2.764

10.  Ulcerative colitis flair induced by mesalamine suppositories hypersensitivity.

Authors:  Hao Ding; Xiao-Chang Liu; Qiao Mei; Jian-Ming Xu; Xiang-Yang Hu; Jing Hu
Journal:  World J Gastroenterol       Date:  2014-04-07       Impact factor: 5.742
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.